Cart
sales@molnova.com
Benralizumab
CAS No. 1044511-01-4
Benralizumab( —— )
Catalog No. M32801 CAS No. 1044511-01-4
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 825 | In Stock |
|
| 5MG | 1416 | In Stock |
|
| 10MG | 2204 | In Stock |
|
| 25MG | 3287 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBenralizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBenralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα).
-
DescriptionBenralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor | Apoptosis | Interleukin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1044511-01-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5(3):00009-2019. Published 2019 Sep 25.?
molnova catalog
related products
-
Ayanin
Ayanin has vasorelaxant activity, it also may have the potential for use in treating allergic asthma. The IC50 value of Ayanin is 2.2microM for inhibiting interleukin IL-4 production from purified basophils. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for respiratory disease researches.
-
Netakimab
Netakimab (BCD 085) is a humanized camel-derived monoclonal antibody targeting interleukin-17A, which can be used to study spondyloarthritis and plaque psoriasis.
-
Brodalumab
Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.
